HC Wainwright & Co. maintains Buy rating on Annexon, $25 price target
HC Wainwright & Co. maintained a Buy rating and $25 price target for Annexon, implying a 633.1% upside from the Oct 16 close of $3.41. The firm highlighted Annexon's pipeline targeting unmet medical needs in autoimmune and neurodegenerative diseases.
How this was made
The 30-second read
Why it matters
The analyst's price target suggests a large upside, but without new trial data the catalyst is primarily sentiment‑driven.
Market read
A new Buy rating with a high target could spark short‑term buying in ANX, but impact is limited to niche biotech investors.
What to watch
No recent clinical data were disclosed; the rating rests on expectations rather than new results.
Background
Annexon is a clinical‑stage biotech focused on complement‑mediated disorders.
Market effects
May lift sentiment for small‑cap biotech stocks.
Limited to U.S. biotech sector.
Minimal.
Counterpoint
The target may be overly optimistic given the company's early‑stage pipeline.
Key entities
- companyAnnexon Inc.
Biotech developing complement pathway therapies.
- analyst_firmHC Wainwright & Co.
Equity research firm issuing the rating.
